The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence

被引:59
|
作者
Xiang, Yu-zhu [1 ]
Xiong, Hui [1 ]
Cui, Zi-lian [1 ]
Jiang, Shao-bo [1 ]
Xia, Qing-hua [1 ]
Zhao, Yong [1 ]
Li, Guan-bin [1 ]
Jin, Xun-bo [1 ]
机构
[1] Shandong Univ, Prov Hosp, Minimally Invas Urol Ctr, Jinan 250021, Peoples R China
关键词
Gleason score; Recurrence; Clinical stage; Aggressiveness; COHORT; IMPACT; MEN;
D O I
10.1186/1756-9966-32-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although a previous meta-analysis reported no association between metabolic syndrome (MetS) and prostate cancer risk, a number of studies suggest that MetS may be associated with the aggressiveness and progression of prostate cancer. However, these results have been inconsistent. This systematic review and meta-analysis investigated the nature of this association. Methods: We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to January 2013 using the keywords "metabolic syndrome" and "prostate cancer". We assessed relative risks (RRs) of the prostate cancer, several parameters of prostate cancer aggressiveness and progression associated with MetS using 95% confidence intervals (95% CIs). Results: The literature search produced 547 hits from which 19 papers were extracted for the meta-analysis. In cancer-free population with and without MetS, the combined adjusted RR (95% CI) of prostate cancer risk and prostate cancer-specific mortality in longitudinal cohort studies is 0.96 (0.85 similar to 1.09) and 1.12 (1.02 similar to 1.23) respectively. In the prostate cancer patients with and without MetS, the combined unadjusted OR (95% CI) of high grade Gleason prostate cancer is 1.44 (1.20 similar to 1.72), the OR of advanced prostate cancer is 1.37 (1.12 similar to 1.68) and the OR of biochemical recurrence is 2.06 (1.43 similar to 2.96). Conclusions: The overall analyses revealed no association between MetS and prostate cancer risk, although men with MetS appear more likely to have high-grade prostate cancer and more advanced disease, were at greater risk of progression after radical prostatectomy and were more likely to suffer prostate cancer-specific death. Further primary studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are required.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] High-grade prostate cancer and finasteride
    Lebdai, Souhil
    Bigot, Pierre
    Azzouzi, Abdel-Rahmene
    BJU INTERNATIONAL, 2010, 105 (04) : 456 - 459
  • [22] Finasteride and High-Grade Prostate Cancer
    Edwards, Jonathan L.
    CANCER PREVENTION RESEARCH, 2009, 2 (02) : 185 - 185
  • [23] Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality
    Burgess, Laura
    Aldrighetti, Christopher M.
    Ghosh, Anushka
    Niemierko, Andrzej
    Chino, Fumiko
    Huynh, Melissa J.
    Efstathiou, Jason A.
    Kamran, Sophia C.
    JAMA NETWORK OPEN, 2022, 5 (05)
  • [24] Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study
    S J Freedland
    R J Hamilton
    L Gerber
    L L Banez
    D M Moreira
    G L Andriole
    R S Rittmaster
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 254 - 259
  • [25] STATIN USE OF THE RISK OF PROSTATE CANCER AND HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE REDUCE STUDY
    Freedland, Stephen
    Gerber, Leah
    Banez, Lionel
    Moreira, Daniel
    Andriole, Gerald
    Rittmaster, Roger
    JOURNAL OF UROLOGY, 2011, 185 (04): : E135 - E135
  • [26] Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study
    Freedland, S. J.
    Hamilton, R. J.
    Gerber, L.
    Banez, L. L.
    Moreira, D. M.
    Andriole, G. L.
    Rittmaster, R. S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (03) : 254 - 259
  • [27] RISK ASSESSMENT: PROSTATE CANCER-SPECIFIC MORTALITY AND BONE METASTASIS FOR PATIENTS TREATED IN THE PROSTATE CANCER SCREENING ERA
    Van Leeuwen, P. J.
    Van Vught, H. A.
    Van Den Bergh, R. C. N.
    Wolters, T.
    Schroder, F. H.
    Roobol, M. J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 42 - 42
  • [28] Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
    Van den Broeck, Thomas
    van den Bergh, Roderick C. N.
    Briers, Erik
    Cornford, Philip
    Cumberbatch, Marcus
    Tilki, Derya
    De Santis, Maria
    Fanti, Stefano
    Fossati, Nicola
    Gillessen, Silke
    Grummet, Jeremy P.
    Henry, Ann M.
    Lardas, Michael
    Liew, Matthew
    Mason, Malcolm
    Moris, Lisa
    Schoots, Ivo G.
    van der Kwast, Theodorus
    van der Poel, Henk
    Wiegel, Thomas
    Willemse, Peter-Paul M.
    Rouviere, Olivier
    Lam, Thomas B.
    Mottet, Nicolas
    EUROPEAN UROLOGY FOCUS, 2020, 6 (02): : 231 - 234
  • [29] Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer
    Wang, Shi-Heng
    Huang, Shu-Pin
    Pan, Yi-Jiun
    Hsiao, Po-Chang
    Li, Chia-Yang
    Chen, Lih-Chyang
    Yu, Chia-Cheng
    Huang, Chao-Yuan
    Lin, Victor C.
    Lu, Te-Ling
    Bao, Bo-Ying
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (05): : 2331 - 2342
  • [30] Cholesterol metabolism and prostate cancer-specific mortality
    Stopsack, Konrad Hermann
    Sinnott, Jennifer A.
    Cerhan, James Robert
    Mucci, Lorelei A.
    Rider, Jennifer R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)